Close Menu

Breaking News

The company plans to use the funds to improve patient engagement and navigation within its Genome Care Delivery technology platform.

OncoCyte will cease further development of a liquid biopsy test that used an immune system interrogation approach to clarify whether patients’ lung nodules are benign.

The Carlsbad, California-based company said that the contract — its third with the EPA — has a potential value of $25 million over five years.

The tests were developed by Psomagen, Acupath Laboratories, and BioTNS, and the nasal swab self-collection kit is offered by Kroger Health.

Irvine, California-based Fluxergy is working with the MGB Center for COVID Innovation to evaluate the firm's research-use-only COVID-19 testing platform.

RenalytixAI's flagship product is KidneyIntelX, which applies artificial intelligence to patient data to aid in the treatment of progressive kidney disease.

Cowen said that Hologic is on track to more than double its Panther system placements to about 500 this year, driven by SARS-CoV-2 test demand.

The platform combines Leica's laser microdissection tool and PBI's pressure cycling tech to enable better extraction and digestion of proteins from biopsies.

The firm said in an SEC document that it received an FDA warning letter in connection with the agency's requirements for its Verigene SP instrument.

The PCR-based test is based on the US Centers for Disease Control and Prevention's CDC 2019-Novel Coronavirus Real-Time RT-PCR Diagnostic Panel.

With a three-pronged approach, a team led by Mount Sinai researchers examined the functional effects of noncoding de novo mutations on cardiac development.

The company will use the funds to support its growth in the custom probiotics market, scale delivery of its products, and publish new studies.

Burning Rock also said it will continue to develop companion diagnostics-related products based on next-generation sequencing technology.

Last week, GenomeWeb's readers were most interested in Invitae's offer to acquire privately held ArcherDx in a deal worth $1.4 billion.

The test is based on the US Centers for Disease Control and Prevention's SARS-CoV-2 panel and detects two regions of the virus' nucleocapsid gene.

A team of researchers in Germany investigated gene expression in airway cells of SARS-CoV-2 patients, finding increased interaction between epithelial and immune cells.

Both tests are authorized for use by any laboratory CLIA certified to perform high-complexity tests, according to the FDA.

News items for the week of June 22, 2020.

The investment bank said CareDx's products are gaining traction and that the stock is positioned for 20 percent to 30 percent growth over the next few years.

The firm used the new loan to pay off an older $7.0 million loan and a $3.0 million promissory note held by Qiagen North American Holdings.

For the three months ended March 31, the firm reported revenues of $9.2 million, up from $6.0 million in the year-ago quarter and beating the consensus Wall Street estimate of $8.9 million.

The firm said that its RAQ SARS-CoV-2 PCR Kit allows the replacement of full nucleic acid extraction with a simple heat treatment, decreasing sample processing time.

Both PCR-based tests are designed to detect SARS-CoV-2 nucleic acid in upper respiratory specimens and may only be performed by their developers.

Developers are improving and expanding the software that has been helping match patients to molecularly targeted drugs at the institute for over three years.

Pages

The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.

NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.

Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.

In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.